文献速递膀胱癌与上尿路尿路上皮癌

大表面积微粒多西他赛治疗高危非肌层浸润性膀胱癌的1/2期试验结果

Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2022-05-16

这项1/2期试验评估了经尿道膀胱肿瘤电切术(TURBT)后直接注射及膀胱内灌注大表面积微粒多西他赛(LSAM-DTX)治疗高危非肌层浸润性膀胱癌的安全性、初步疗效和免疫效应。19例受试者入组,直接注射和膀胱内灌注LSAM-DTX耐受良好;高剂量及扩展队列的中位无复发生存期显著延长至12.2个月(9例,中位随访12.4个月),而最低3个剂量递增队列为5.4个月(10例,中位随访8.6个月)(p<0.05,风险比0.29)。

要点

  • TURBT后直接注射联合膀胱内灌注LSAM-DTX在高危非肌层浸润性膀胱癌中耐受良好。
  • 高剂量及扩展队列中位无复发生存期为12.2个月,最低3个剂量递增队列为5.4个月(p<0.05,HR 0.29)。
  • LSAM-DTX治疗后肿瘤微环境抗肿瘤免疫细胞增加,PD-1、PD-L1和CTLA-4免疫检查点靶点升高。

核心结论

  • TURBT后直接注射及膀胱内灌注LSAM-DTX耐受良好,在高危非肌层浸润性膀胱癌患者中显示出临床缓解。
  • LSAM-DTX治疗后有利的免疫细胞浸润和检查点受体增加值得单独研究以及与免疫检查点抑制剂联合治疗的研究。

研究设计与样本

  • 开放标签3+3剂量递增试验,并在高剂量组额外入组。
  • 19例受试者入组,其中14例有既往卡介苗暴露史,16例有≥1次既往TURBT史。
  • TURBT后受试者接受直接注射LSAM-DTX至切除部位及膀胱内LSAM-DTX,随后进行6周诱导和3周维持膀胱内LSAM-DTX疗程。
  • 通过细胞学、膀胱镜或活检评估肿瘤复发;治疗前后进行血液药代动力学分析和肿瘤微环境多重免疫荧光分析。

主要发现

  • 直接注射和膀胱内LSAM-DTX耐受良好。
  • 最低3个剂量递增队列的中位无复发生存期为5.4个月(10例患者,中位随访8.6个月)。
  • 高剂量及扩展队列的中位无复发生存期显著增加至12.2个月(9例患者,中位随访12.4个月)(p<0.05,风险比0.29)。
  • 全身多西他赛暴露可忽略不计,肿瘤微环境中抗肿瘤免疫细胞增加,同时PD-1、PD-L1和CTLA-4免疫检查点抑制剂靶点升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the safety, preliminary efficacy, and immune effects of large surface area microparticle docetaxel (LSAM-DTX) administered by direct injection after transurethral resection of bladder tumor (TURBT), and by intravesical instillation in high-risk nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: The trial followed an open-label 3+3 dose escalation with additional enrollment at the high dose. After TURBT, subjects received direct injection LSAM-DTX into the resection site and intravesical LSAM-DTX, followed by 6-week induction and 3-week maintenance intravesical LSAM-DTX courses. Tumor recurrence was evaluated by cytology, cystoscopy, or biopsy. Pharmacokinetic analysis of blood and multiplex immunofluorescence of tumor microenvironment occurred pre- and post-LSAM-DTX. RESULTS: Nineteen subjects were enrolled, 14 with prior bacillus Calmette-Guérin exposure and 16 with ≥1 prior TURBT. Direct injection and intravesical LSAM-DTX were well tolerated. In the 3 lowest dose escalation cohorts the median recurrence-free survival was 5.4 months (10 patients, median followup 8.6 months). In the high-dose and expansion cohorts median recurrence-free survival was significantly increased (p <0.05, hazard ratio 0.29) to 12.2 months (9 patients, median followup 12.4 months). Systemic docetaxel exposure was negligible and increases in antitumor immune cells were found in the tumor microenvironment along with elevations in the PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitor targets. CONCLUSIONS: Post-TURBT direct injection and intravesical LSAM-DTX were well tolerated and demonstrated clinical response for patients with high-risk nonmuscle-invasive bladder cancer. Favorable immune cell infiltration and checkpoint receptor increases following LSAM-DTX treatment warrants investigation alone as well as in combination with immune checkpoint inhibitor therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kates M, Mansour AM, Lamm DL, et al. Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. J Urol. 2022. PMID: 35574612. doi:10.1097/JU.0000000000002778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。